to assess neurocognitive function was administered before and 1 month after the procedure. Results Nineteen patients (54 %) developed new cerebral ischemic lesions after carotid artery stenting. Contrast enhancement of the plaque was greater in the patients with post-procedural microembolization than in those without it [maximum signal intensity 26 ± 7.7 vs. 21 ± 5.2, respectively, (p = 0.039), mean signal intensity, 20.7 ± 6.1 vs. 16.5 ± 5.3, respectively (p = 0.048)]. No correlation was found between neurocognitive test scores and microembolization or plaque enhancement. Conclusion Contrast enhancement of the carotid plaque is strongly associated with post-procedural microembolization and for this reason it can be considered a reliable tool for an accurate selection of patients undergoing this endovascular treatment. However, the neurocognitive test scores performed in this study are not enough sensible to appreciate the impact of the neurological injury on the day life activities.
still unclear because, in addition to the presence of many potential confounders, neurologic assessment often fails to capture and predict changes in cognitive function [3, 4] . A valuable technique to define plaque enhancement and potential risk of embolization is contrast-enhanced ultrasound (CEUS) [5] [6] [7] [8] , while diffusion-weighted magnetic resonance imaging (DW-MRI) is a highly reliable imaging method for detecting recent ischemic brain lesions [9] . The aim of this study is to compare plaque enhancement as evaluated by CEUS with new cerebral ischemic lesions after CAS and to define the clinical impact of the neurological injury.
Methods
The prospective study has been approved by an ethic committee and it has been performed in accordance with the ethical standards laid down in the Declaration of Helsinki and its later amendments. All patients gave their informed consent prior to their inclusion in the study. We enrolled 35 consecutive patients (28 males, 7 females; mean age 73.2 ± 5) treated with CAS for severe carotid artery stenosis. Three patients (8 %) were symptomatic before the procedure [transient ischemic attack (TIA) with left hemiplegia in 2, and dysarthria and transient right arm paresthesia in 1].
Inclusion criteria
Degree of carotid stenosis >70 % according to North American Symptomatic Carotid Endarterectomy Trial (NASCET) or with a peak of systolic velocity >200 cm/s; symptomatic and asymptomatic patients; contraindication to carotid endoarterectomy.
Exclusion criteria
Secondary carotid artery stenting; occlusion of the ipsilateral middle cerebral artery (MCA); cerebral imaging of haemorragic stroke; patients with neurological impairment >15 according to National Institute of Health Stroke Score (NIHSS).
The indications for CAS were: history of neck radiotherapy (n = 3); previous neck surgery (n = 5); patient's personal choice (n = 12); anatomically unfavourable bifurcation (n = 3); contralateral vocal cord paralysis (n = 2); and medical/anaesthesiological contraindication to open surgery (n = 10) ( Table 1) .
Imaging and cognitive assessment
Preoperative echo-Doppler ultrasound scans (MyLab 25Gold, Esaote ® ) were obtained to define plaque morphology and measure the degree of stenosis [10] , followed by CEUS to evaluate plaque enhancement. Preoperative neurologic assessment included head magnetic resonance (MR) examination (Philips Achieva 1.5 T, head coil) and neuropsychological test [Ray auditory verbal learning test (RAVLT)]. The MR protocol was performed with T1-weighted sagittal, T2-weighted axial, fluid-attenuated inversion recovery (FLAIR) axial and diffusion-weighted imaging (DWI) with quantitive analysis using apparent diffusion coefficient (ADC) maps. Ischemic lesions of the cerebral hemispheres, size, and location were recorded and analyzed by a single operator. 
CAS procedure
Angiography was performed in local anesthesia after the administration of a load dose of 300 mg clopidogrel, through a percutaneous femoral access; a cerebral protection filter (SpiderFX ® , Covidien, Plymouth, MN) was then deployed into the internal carotid downstream the stenosis. CAS was performed with a Bard Vivexx ® stent (Bard, New Providence, NJ) in 30 cases, a Carotid Wallstent ® (Boston Scientific, Natick, MA) in 3 and an Xact ® (Abbott Vascular, Redwood City, CA) in 2. Postprocedural hemostasis was achieved with manual compression. A 1-month course of double antiplatelet therapy [clopidogrel 75 mg and acetylsalicylic acid (ASA) 100 mg] was initiated, followed by lifelong single antiaggregation therapy with ASA.
Postprocedural patient evaluation and follow-up
Before discharge, a second DW-MRI study was performed 48 h after CAS to detect potentially new brain ischemic lesions. Follow-up examination included echo-Doppler ultrasonography (at 1, 6, 12 months, and then yearly thereafter) performed by the same operator and clinical and cognitive evaluation (RAVLT) at 1 month after the procedure.
Data collection and statistical analysis
All data from CEUS, DW-MRI and RAVLT scores were collected blinded of the other results to avoid any confounders. CEUS images were analyzed with Quontrast 4.0 ® dedicated software (Bracco, Milan, Italy), as described in a previous study [5] , and the maximum and mean signal intensity (SI max and SI mean) were calculated. Pre and post procedural DW-MRI images were compared to detect the presence of new ischemic lesions and to define the side (ipsilateral-contralateral), size, location, and number (Fig. 1) . Moreover, we determined a cut-off value for SI max and SI mean with Cohen k and we confirmed the results with the maximization of the harmonic mean of the data distribution.
Primary end-points of the study are: the correlation between the carotid plaque enhancement (CEUS) with post-procedural cerebral embolization (DW-MRI) and to evaluate the the clinical impact of the neurological ischemic injury (DW-MRI) on the procedural and memory cerebral functions (RAVLT).
Secondary end-points are: the technical success of the procedure, post-procedural neurological complications and the rate of restenosis at 1 year of follow up. For the statistical analysis, the variables, reported as mean ± standard deviation (SD), were compared with the non-parametric Mann-Whitney test. The categorical variables, reported as counts and percentages with 95 % confidence interval, arranged in row × column contingency tables, were analyzed with the Chi square test (with Yates' correction for 2 × 2) or Fisher's exact test. The risk ratio (RR) was computed with its 95 % confidence interval (CI). Statistical significance was set at p < 0.05. For p > 0.05, the test power and relative false negative probability were estimated.
Results
The degree of stenosis, measured according to NAS-CET and as evaluated with echo-Doppler ultrasound, was 77 ± 4.5 %. CAS was technically successful in all patients; no residual stenosis, carotid dissection, elastic recoil or stent fracture was seen on the postprocedural angiography images. DW-MRI revealed silent ischemic brain lesions in nine patients (25 %) before CAS. The postprocedural DW-MRI control scans detected new ipsilateral ischemic lesions (from 1 to 5 lesions) in 19 patients (54 %). Neurologic postprocedural complications arose in two patients (6 %): one case of facial paresthesia which completely regressed before hospital discharge and one case of contralateral brachial weakness and numbness which partially resolved at 6-months and totally regressed at one year follow-up. Comparison of the CEUS images showed a statistical difference in the SI max and SI mean between the patients with and Table 2) .
At 30 days, follow up with echo-Doppler ultrasound, we found two patients (5 %) with a moderate degree of intrastent restenosis that remained stable at 6 months and 1 year control. There was no statistically significant variation of RAVLT scores for the patients with post-procedural microembolization (8 ± 4.6 before CAS vs. 8 ± 5.5 after CAS; p = 0.53) or for those without it (7.4 ± 5.4 before CAS vs. 7.7 ± 4 after CAS; p = 0.62).
Discussion
There is a growing body of evidence that CEUS evaluation of carotid artery lesions can be a cost-effective and reliable method to define plaque vulnerability and predict the risk of embolization [5, 6, 11] . Because of the significantly higher risk of periprocedural embolization during primary CAS as compared with carotid endoarterectomy, CEUS can be advantageously applied as a useful imaging system for Table 2 Results of the study between patients who developed post procedural cerebral ischemic injury (Microembolization+) and those without post-procedural ischemic injury (Microembolization−) * p value <0.05. Below the SI max and SI mean values we reported the distribution of the study population according to the cut-off estimated for each variable. RAVLT p value was evaluated in the same group before and after CAS the assessment of plaque morphology [12] . Stent deployment exerts strong radial forces on arterial walls, augmenting the risk of plaque fragmentation and cerebral embolization. Unfortunately, even the systematic use of cerebral protection filters appears to be insufficient to prevent this complication [13] . DW-MRI is a highly sensitive method for the early detection of ischemic brain regions by virtue of its ability to identify cytotoxic edema, one of the first hallmarks of brain injury [9] . Data from the literature suggest that, as compared with traditional carotid endarterectomy, postprocedural microembolization is associated with faster neurocognitive decline particularly in memory function [3, 4] . Therefore, we compared neuropsychological RAVLT score before CAS and at 1-month follow-up. We found a direct association between plaque enhancement and postprocedural microembolization, which is consistent with our previous findings on plaque vulnerability and with published data [5, 6] . In detail, patients with a SI max value of more than 26 have a significantly higher risk of developing cerebral microembolization with CAS. The cut-off values of SI mean do not reach statistical significance (p = 0.2) however the distribution of values reveal a trend towards a difference between the two groups and this result might be attributable to the small population size.
We found no correlation between CEUS results and the number of the cerebral lesions or a significant difference between the number of lesions and clinically relevant neurological symptoms. This could be partially explained by the presence of silent parenchymal brain regions or hemodynamic mechanisms of brain compensation ("washout" phenomenon) [14, 15] . The RAVLT scores failed to reveal a decline in memory function in patients with microembolization at 1 month follow-up. This finding contrasts with previous observations [3, 4] and is partially attributable to the specific neurocognitive domain investigated, and patient compliance. To the best of our knowledge, this is the first study that directly compares CEUS evaluation of the carotid plaque with CAS post-procedural microembolization. Despite the relatively small sample size, our data are supported by a high statistical significance. As this is an ongoing study, it is important to confirm these results on a larger population study and to investigate other neurocognitive domains with multiple tests and for a longer follow-up.
Conclusion
Contrast enhancement of the atherosclerotic plaque is strongly associated with the risk of microembolization after carotid stenting deployment. For this reason CEUS could become a mandatory assessment to select patients who benefit most from CAS. Further neurological tests are recommended to appreciate the clinical impact of the cerebral ischemic damage after the procedure.
